THOMAS MONATH to Yellow fever virus
This is a "connection" page, showing publications THOMAS MONATH has written about Yellow fever virus.
Connection Strength
7.526
-
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015 Jan 01; 33(1):62-72.
Score: 0.427
-
Yellow fever. J Clin Virol. 2015 Mar; 64:160-73.
Score: 0.427
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.402
-
Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes. Virus Res. 2013 Sep; 176(1-2):280-4.
Score: 0.384
-
Treatment of yellow fever. Antiviral Res. 2008 Apr; 78(1):116-24.
Score: 0.264
-
Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006 Oct; 75(4):659-63.
Score: 0.244
-
In Vivo Characterization and Tissue Tropism of a Wild-Type Yellow Fever Virus Isolate from the 2017-2018 Brazilian Outbreak in C57BL/6 IFNAR1-/- Mice. Viruses. 2025 Sep 29; 17(10).
Score: 0.228
-
Yellow fever vaccine. Expert Rev Vaccines. 2005 Aug; 4(4):553-74.
Score: 0.225
-
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
Score: 0.218
-
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol. 2004 Nov; 78(22):12497-507.
Score: 0.214
-
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004 Nov; 71(5):639-45.
Score: 0.214
-
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
Score: 0.211
-
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
Score: 0.206
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.205
-
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
Score: 0.181
-
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
Score: 0.177
-
Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 2002 Jan 15; 20(7-8):996-9.
Score: 0.176
-
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001 Aug; 75(16):7290-304.
Score: 0.171
-
Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med. 2001 Aug; 7(8):350-4.
Score: 0.171
-
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
Score: 0.157
-
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
Score: 0.154
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
Score: 0.146
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
Score: 0.145
-
Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017 03; 17(3):248-250.
Score: 0.124
-
Stability of yellow fever vaccine. Dev Biol Stand. 1996; 87:219-25.
Score: 0.116
-
Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013 Oct; 19:292-311.
Score: 0.096
-
Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
Score: 0.095
-
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
Score: 0.085
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.085
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.083
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
Score: 0.075
-
Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am J Trop Med Hyg. 1989 Jun; 40(6):663-8.
Score: 0.073
-
Use of a surrogate chimeric virus to detect West Nile virus-neutralizing antibodies in avian and equine sera. Clin Vaccine Immunol. 2009 Jan; 16(1):134-5.
Score: 0.071
-
Yellow fever: 100 years of discovery. JAMA. 2008 Aug 27; 300(8):960-2.
Score: 0.070
-
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
Score: 0.066
-
A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
Score: 0.063
-
Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984. Bull World Health Organ. 1987; 65(6):855-60.
Score: 0.062
-
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol. 1986 Dec; 60(3):1153-5.
Score: 0.062
-
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
Score: 0.059
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
Score: 0.059
-
Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. J Clin Microbiol. 1986 Jan; 23(1):129-34.
Score: 0.058
-
Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg. 1984 Jul; 33(4):695-8.
Score: 0.052
-
High fidelity of yellow fever virus RNA polymerase. J Virol. 2004 Jan; 78(2):1032-8.
Score: 0.050
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.050
-
Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus). Am J Trop Med Hyg. 2003 Jul; 69(1):78-80.
Score: 0.049
-
Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol. 1983 Mar; 64 Pt 3:627-37.
Score: 0.048
-
Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983 Feb; 125(1):8-17.
Score: 0.047
-
Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
Score: 0.047
-
Epidemiology and ecology of yellow fever virus. Adv Virus Res. 2003; 61:291-315.
Score: 0.047
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.044
-
Yellow fever: an update. Lancet Infect Dis. 2001 Aug; 1(1):11-20.
Score: 0.043
-
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
Score: 0.041
-
Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
Score: 0.028
-
Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol. 1994 Feb; 75 ( Pt 2):417-23.
Score: 0.025
-
Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts. Trans R Soc Trop Med Hyg. 1974; 68(1):30-8.
Score: 0.025
-
Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg. 1991 Jul; 45(1):1-43.
Score: 0.021
-
Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol. 1990 Oct; 71 ( Pt 10):2301-6.
Score: 0.020
-
Viral vectors for malaria vaccine development. Vaccine. 2007 Mar 30; 25(14):2567-74.
Score: 0.015
-
Genetic heterogeneity of yellow fever virus strains from Africa and the Americas. J Gen Virol. 1986 Jan; 67 ( Pt 1):209-13.
Score: 0.014
-
Glad tidings from yellow fever research. Science. 1985 Aug 23; 229(4715):734-5.
Score: 0.014
-
Detection of yellow fever virus in serum by enzyme immunoassay. Am J Trop Med Hyg. 1984 Jan; 33(1):151-7.
Score: 0.013
-
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001 Jul 14; 358(9276):91-7.
Score: 0.011
-
[Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):31-43.
Score: 0.010
-
[Yellow fever in Senegal from 1976 to 1980 (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):45-51.
Score: 0.010
-
Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med Hyg. 1981; 75(2):282-6.
Score: 0.010
-
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. Am J Trop Med Hyg. 1980 Jul; 29(4):624-34.
Score: 0.010
-
Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
Score: 0.006
-
Importance of nonhuman primates in yellow fever epidemiology in Nigeria. Trop Geogr Med. 1973 Mar; 25(1):28-38.
Score: 0.006
-
The 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemic. Bull World Health Organ. 1973; 49(2):123-8.
Score: 0.006
-
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ. 1973; 49(3):235-44.
Score: 0.006
-
Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol. 1989 Dec; 40(4):396-9.
Score: 0.005
-
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900.
Score: 0.003
-
Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations. Am J Trop Med Hyg. 1980 Sep; 29(5):929-40.
Score: 0.003
-
Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. II. Entomological investigations and viruses isolated. Trans R Soc Trop Med Hyg. 1974; 68(1):39-43.
Score: 0.002